Navigation Links
MiMedx Signs Distribution Agreement With Zimmer
Date:9/18/2014

MARIETTA, Ga., Sept. 18, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it has entered into a distribution agreement with Zimmer, Inc.  Through the agreement, MiMedx will provide its dehydrated human amnion/chorion membrane ("dHACM") allograft products to Zimmer to be marketed non- exclusively on a private label basis.

The MiMedx dHACM allografts, processed utilizing the Company's proprietary PURION® process, will be provided to Zimmer for marketing under Zimmer's private-label.  Through-out the United States, Zimmer will market and sell the private-labeled allografts to Zimmer customers and end-users.  The distribution agreement encompasses a range of musculoskeletal applications to include reconstructive, sports medicine, trauma, extremities and spinal applications.

Parker H. Petit, MiMedx Chairman and CEO, said, "We are very pleased about the opportunity to partner with Zimmer.  This agreement will facilitate a sizable expansion of the physicians and patients that will now have access to our dHACM allografts.  The breadth of the applications included in the agreement and the large base of physicians, hospitals and other medical facilities served by Zimmer will enhance the presence of our allografts in the musculoskeletal sector of the market."

"Zimmer has a stellar reputation and is a recognized leader in bringing new technologies and applications to the forefront to serve the reconstructive, sports medicine, trauma, extremities and spinal markets," said Bill Taylor, MiMedx President and COO.  "Our goal is to reach as many patients as possible that will benefit from the regenerative properties of our allografts. Our relationship with Zimmer will allow us to further the realization of that goal."

About Zimmer

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, dental implants, and related surgical products.  Zimmer has operations in more than 25 countries around the world and sells products in more than 100 countries.  Zimmer's 2013 sales were approximately $4.6 billion.  Zimmer is supported by the efforts of more than 9,000 employees worldwide.

About MiMedx

MiMedx® is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane.  "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself.  Our biomaterial platform technologies include AmnioFix® and EpiFix®, our tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx® is the leading supplier of amniotic tissue, having supplied over 275,000 allografts to date for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

Safe Harbor Statement

This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes.  Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements include, but are not limited to the agreement facilitating a sizable expansion of the physicians and patients that have access to the Company's dHACM allografts, the effect of the breadth of the applications included in the agreement and the large base of physicians, hospitals and other medical facilities served by Zimmer on the presence of the Company's allografts in the musculoskeletal sector of the market, and the extent to which the MiMedx relationship with Zimmer will allow the Company to further the realization of its goal to reach as many patients as possible. These statements are based on current information and belief, and are not guarantees of future performance.  Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that the agreement may not facilitate a sizable expansion of the physicians and patients that have access to the Company's dHACM allografts, that the breadth of the applications included in the agreement and the large base of physicians, hospitals and other medical facilities served by Zimmer will not enhance the presence of the Company's allografts in the musculoskeletal sector of the market, that the MiMedx relationship with Zimmer will fail  to further the realization of the Company's goal to reach as many patients as possible, and the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2013.  By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company's disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.


'/>"/>
SOURCE MiMedx
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. MiMedx Announces Record Second Quarter Results
2. MiMedx Files Its Initial Investigational New Drug Application
3. MiMedx Announces Next Steps After Discussions With The FDA
4. Seven Poster Abstracts Highlight MiMedx Allografts at the 10th Annual Desert Foot Conference
5. MiMedx to meet with FDA in Mid-October
6. MiMedx Announces Conference Call To Discuss FDA "Untitled Letter" And Reiterate Guidance
7. MiMedx Addresses FDA Untitled Letter And Reiterates 2013 And 2014 Guidance
8. MiMedx Group, Inc. Announces Release Date for 2013 Second Quarter Results
9. MiMedx Announces 2012 Results
10. MiMedx Group to Present at the 6th Annual OneMedForum
11. MiMedx Group to Present at the Stifel Nicolaus 2012 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2021)... ... March 29, 2021 , ... The University of Texas Health Science Center ... San Antonio Multispecialty and Research Hospital, a destination center for research and treatment of ... In a nod to the COVID-19 pandemic, the ceremony was held virtually. , William ...
(Date:3/30/2021)... ... March 29, 2021 , ... Iora Health ... primary care, has partnered with Devoted Health , one of the fastest-growing ... across Maricopa County and provides seniors with the highest-quality care and experience possible, ...
(Date:3/30/2021)... CITY (PRWEB) , ... March 29, 2021 , ... ... has joined the Vaccine Credential Initiative (VCI), a group bringing together leading health ... record of vaccination status, based on open, interoperable standards. By joining the VCI ...
Breaking Medicine Technology:
(Date:3/30/2021)... , ... March 29, 2021 , ... ... the 21st Century , A Virtual Workshop Presented by WCG FDAnews and Cerulean ... 4:30 pm EDT, https://wcg.swoogo.com/modern-sop-and-quality-systems , Are one’s SOPs written for the ...
(Date:3/30/2021)... ... March 29, 2021 , ... According to data released ... reproductive age (13-44) in need of publicly funded contraception live in counties impacted by ... Colorado’s 64 counties have lost some of their Title X resources. , The ...
(Date:3/30/2021)... ... March 29, 2021 , ... Health Literacy Innovations (HLI), a ... confusion due to low health literacy today announces a new partnership with the ... work with ACAP’s member Safety Net Health Plans, those that provide comprehensive health ...
(Date:3/30/2021)... ... ... Dr. Colin Campbell is proud to announce the 1 year anniversary in their new state ... internal medicine and is a primary care specialist who has been practicing for 23 years. ... keep South Jersey healthy one patient at a time. , “Over the past year, Dr. ...
(Date:3/30/2021)... ... March 30, 2021 , ... The COVID-19 ... and survivors; their families; and their caregivers. Crossroads4Hope is addressing the needs of ... emotional support system, MyGo2Support, which meets needs of people impacted by cancer, no ...
Breaking Medicine News(10 mins):